In mantle cell lymphoma, STAT5B also STAT5B was associated with drug resistance.[32] Another result suggested that STAT5B could be open novel therapeutic target for drug development.[33] Therefore, STAT5B may act as biomarker for drug screening in breast cancer, and further study should be performed to verify this. This evidence concerns the gene STAT5B and breast carcinoma.